Beware of False “Cures” for Autism

What you need to know

Unapproved and Potentially Harmful Products

Autism Spectrum Disorder (ASD) affects about 1 in 68 children, and while early behavioral therapies can help improve symptoms, there is no cure for autism. Unfortunately, some companies promote unproven products that falsely claim to treat or even cure ASD — and some can be dangerous.

What the FDA Wants You to Know

The FDA has acted against companies marketing unapproved and potentially harmful products that claim to treat autism. These include:

  • Chelation Therapies (sprays, drops, baths): Meant to remove “toxins,” but can dangerously deplete essential minerals.
  • Hyperbaric Oxygen Chambers: Only approved for specific medical uses — not autism.
  • Detoxifying Clay Baths: Claim to “pull out toxins” through the skin — no evidence they help.
  • MMS (chlorine dioxide), raw camel milk, essential oils, and others: Heavily marketed, not scientifically proven, and can pose real health risks.

FDA-Approved Treatments Exist — But Only for Specific Symptoms

There are two FDA-approved medications to manage irritability associated with autism:

  • Risperidone (ages 5–16)
  • Aripiprazole (ages 6–17)

These medications help with specific symptoms — not autism itself — and should only be used under medical supervision.

Real Help for ASD

  • Early behavioral interventions can improve communication and daily living skills.
  • Treatment should be tailored to the individual’s needs.
  • Work with licensed healthcare professionals, not unregulated products.

Watch Out for These Red Flags

  • “Quick fixes” or “miracle cures”
  • Claims to treat a wide range of unrelated conditions
  • Personal stories with no scientific backing
  • Secret ingredients or “breakthrough science”

If it sounds too good to be true, it probably is.

If you have questions about therapies or treatments, talk to a doctor who specializes in autism. Trust science — not sales pitches.

Read more here

Camber Recalls Atovaquone Oral Suspension USP

Camber Recalls Atovaquone Oral Suspension USP for Potential Contamination Camber Pharmaceuticals Inc. recently issued a voluntary nationwide recall of Atovaquone Oral Suspension USP due to potential contamination. The recall was announced by the U.S. Food and Drug...

Prodigy Proclaim Spinal Cord Stimulation Systems

Significant advancement for chronic pain treatment On February 15, 2023, the U.S. Food and Drug Administration (FDA) announced the approval of the Prodigy Proclaim and Proclaim XR Spinal Cord Stimulation (SCS) systems. This approval marks a significant step forward in...

Exposure to toxic materials during hemodialysis and dialysis

FDA announcement The US Food and Drug Administration (FDA) issued an announcement on March 7 to update its May 2022 letter to healthcare providers regarding the potential risks of exposure to toxic compounds when using hemodialysis and peritoneal dialysis. This update...